Comparative study of p53 expression in primary invasive ductal carcinoma of the pancreas between Chinese and Japanese

Pancreas

Volumn 17, Issue 3, 1998, Pages 229-237

  Dong, Ming ^a   Nio, Yoshinori ^a   Sato, Yoshitoshi ^a   Tamura, Katsuhiro ^a   Song, Mao Min ^b   Tian, Yu Lin ^b   Dong, Yu Ting ^b  

^a SHIMANE UNIVERSITY   (Japan)

^b CHINA MEDICAL UNIVERSITY   (China)

Author keywords

Epidemiology; Immunohistochemistry; P53; Pancreatic cancer

Indexed keywords

PROTEIN P53;

ADULT; AGE; AGED; ARTICLE; CANCER GRADING; CANCER STAGING; CHINESE; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INVASIVE CARCINOMA; JAPAN; MAJOR CLINICAL STUDY; MALE; PANCREAS CARCINOMA; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; SEX DIFFERENCE;

EID: 0031719226     PISSN: 08853177     EISSN: None     Source Type: Journal    
DOI: 10.1097/00006676-199810000-00002     Document Type: Article

References (44)

1. Suwa H, Toshimura T, Tamaguchi N, et al. K-ras and p53 alterations in genomic DNA and transcripts of human pancreatic adenocarcinoma cell lines. Jpn J Cancer Res 1994;85:1005-14.
2. Tominaga S. Epidemiology of pancreatic cancer. Jpn J Cancer Chemother 1992;19:2297-303.
3. Jin F, Devesa SS, Zheng W, Blot WJ, Fraumeni JF Jr, Gao YT. Cancer incidence trends in urban Shanghai, 1972-1989. Int J Cancer 1993;53:764-70.
4. Gansauge S, Gansauge F, Beger HG. Molecular oncology in pancreatic cancer. J Mol Med 1996;74:313-20.
5. Casey G, Yamanaka Y, Friess H, et al. p53 gene mutations are common in pancreatic cancer and absent in chronic pancreatitis. Cancer Lett 1993;69:151-60.
6. Harris CC, Hollstein M. Clinical implications of the p53 tumor-suppressor gene. N Engl J Med 1993;329:1318-27.
7. DiGiuseppe JA, Hruban RH, Goodman SN, et al. Overexpression of p53 protein in adenocarcinoma of the pancreas. Am J Clin Pathol 1994;101:684-8.
8. van Es JM, Polak MM, van den Berg FM, et al. Molecular markers for diagnostic cytology of neoplasms in the head region of the pancreas: mutation of K-ras and overexpression of the p53 protein product. J Clin Pathol 1995;48:218-22.
9. Maacke H, Kessler A, Schmiegel W, et al. Overexpression of p53 protein during pancreatitis. Br J Cancer 1997;75:1501-4.
10. Suwa H, Ohshio G, Okada N, et al. Clinical significance of serum p53 antigen in patients with pancreatic carcinomas. Gut 1997;40: 647-53.
11. Harada N, Gansauge S, Gansauge F, et al. Nuclear accumulation of p53 correlates significantly with clinical features and inversely with the expression of the cyclin-dependent kinase inhibitor p21(WAF1/CIP1) in pancreatic cancer. Br J Cancer 1997;76:299-305.
12. Zhang SY, Ruggeri B, Agarwal P, et al. Immunohistochemical analysis of p53 expression in human pancreatic carcinomas. Arch Pathol Lab Med 1994;118:150-4.
13. Beahrs OH, Henson DE, Hutter RVP, Kennedy BJ (eds). Handbook for staging of cancer (from Manual for staging of cancer, 4th ed.). Philadelphia: J. B. Lippincott, 1993:125-8.
14. Lane DP, Benchimol S, P53: oncogene or anti-oncogene? Genes Dev 1990;4:1-8.
15. Song MM, Nio Y, Sato Y, Tamura K, Furuse K. Clinicopathological significance of K-ras point mutation and p21 expression in benign and malignant exocrine tumors of the human pancreas. Int J Pancreatol 1996;20:27-35.
16. Shi SR, Key ME, Kalra KL. Antigen retrieval in formalin-fixed, paraffin-embedded tissues: an enhancement method for immunohistochemical staining based on microwave oven heating of tissue sections. J Histochem Cytochem 1991;39:741-8.
17. Statistics Bureau, Management and Coordination Agency. Japan statistical yearbook, 42nd ed. Tokyo: Japan Statistical Association, 1992:40-1.
18. Population Census Office. Tabulation of the 1990 population census of Liaoning Province, 1st ed. Beijing: China Statistical Publishing House, 1992:497-9.
19. Expert Forum. Progress in diagnosis and treatment for carcinoma of pancreas. Chinese J Pract Surg 1995;15:228-30.
20. Sinicrope FA, Evans DB, Leach SD, et al. bc12 and p53 expression in resectable pancreatic adenocarcinomas: association with clinical outcome. Clin Cancer Res 1996;2:2015-22.
21. Yokoyama M, Yamanaka Y, Friess H, Buchler M, Korc M. p53 expression in human pancreatic cancer correlates with enhanced biological aggressiveness. Anticancer Res 1994;14:2477-84.
22. Lee CS, Rush M, Charalambous D, Rode J. Immunohistochemical demonstration of the p53 tumor suppressor gene product in cancer of the pancreas and chronic pancreatitis. J Gastroenterol Hepatol 1993;8:465-6.
23. Lundin J, Nordling S, von Boguslawsky K, Roberts PJ, Haglund C. Prognostic value of immunohistochemical expression of p53 in patients with pancreatic cancer. Oncology 1996;53:104-11.
24. Hoshi T, Imai M, Ogawa K. Frequent K-ras mutations and absence of p53 mutations in mucin-producing tumors of the pancreas. J Surg Oncol 1994;55:84-91.
25. Sato Y, Nio Y, Song MM, et al. p53 protein expression as prognostic factor in human pancreatic cancer. Anticancer Res 1997;17: 2779-88.
26. Ahlgren LD. Epidemiology and risk factors in pancreatic cancer. Semin Oncol 1996;23:241-50.
27. Olsen GW, Mandel JS, Gibson RW, Wattenberg LW, Schuman LM. A case-contrast study of pancreatic cancer and cigarettes, alcohol, coffee and diet. Am J Public Health 1989;79:1016-9.
28. Nishi M, Ohba S, Hirata K, Miyake H. Dose-response relationship between coffee and the risk of pancreatic cancer. Jpn J Clin Oncol 1996;26:42-8.
29. Visakorpi T, Kalliomiemi O-P, Heikkinen TK, et al. Small subgroup of aggressive, highly proliferative prostatic carcinomas defined by p53 accumulation. J Natl Cancer Inst 1992;84:883-7.
30. Isola J, Visakorpi T, Holli K, et al. Association of overexpression of tumor suppressor protein p53 with rapid cell proliferation and poor prognosis in node-negative breast cancer patients. J Natl Cancer Inst 1992;84:1109-14.
31. Donehower LA, Bradley A. The tumor suppressor p53. Biochim Biophys Acta 1993;1155:181-205.
32. Quinlan DC, Davidson AG, Summaers CL, Warden HE, Doshi HM. Accumulation of p53 protein correlates with a poor prognosis in human lung cancer. Cancer Res 1992;52:4828-31.
33. Yamaguchi A, Kurosaka Y, Fushida S, et al. Expression of p53 protein in colorectal cancer and its relationship to short-term prognosis. Cancer 1992;70:2778-84.
34. Martin HM, Filipe MI, Morris RW, Lane DP, Silvestre F. p53 expression and prognosis in gastric carcinoma. Int J Cancer 1992; 50:859-62.
35. Nakamori S, Yashima K, Murakami Y, et al. Association of p53 gene mutations with short survival in pancreatic adenocarcinoma. Jpn J Cancer Res 1995;86:174-81.
36. Wu XW, Bayle H, Olsen D, Levine AJ. The p53-mdm-2 autoregulatory feedback loop. Genes Dev 1993;7:1126-32.
37. Frebourg T, Friend SH. The importance of p53 gene alterations in human cancer: Is there more than circumstantial evidence? J Natl Cancer Inst 1993;85:1154-7.
38. Momand J, Zambetti GP, Olson DC, George D, Levine AJ. The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation. Cell 1992;69:1237-45.
39. Orazi A, Kahsai M, John K, Neiman RS. p53 overexpression in myeloid leukemic disorders is associated with increased apoptosis of hematopoietic marrow cells and ineffective hematopoiesis. Modern Pathol 1996;9:48-52.
40. Benhattar J, Cerottini JP, Saraga E, Merrez G, Givel JC. p53 mutations as a possible predictor of response to chemotherapy in metastatic colorectal carcinomas. Int J Cancer 1996;69:190-2.
41. Eliopoulos AG, Kerr DJ, Herod J, et al. The control of apoptosis and drug resistance in ovarian cancer: influence of p53 and Bcl-2. Oncogene 1995;11:1217-28.
42. Linn SC, Honkoop AH, Hoekman K, van der Valk P, Pinedo HM, Giaccone G. p53 and P-glycoprotein are often co-expressed and are associated with poor prognosis in breast cancer. Br J Cancer 1996;74:63-8.
43. Petty RD, Cree IA, Sutherland LA, et al. Expression of the p53 tumour suppressor gene product is a determinant of chemosensitivity. Biochem Biophys Res Commun 1994;28:264-70.
44. Muller H, Eppenberger U. The dual role of mutant p53 protein in chemosensitivity of human cancers. Anticancer Res 1996;16: 3845-8.